Soligenix, Inc. announced today that the Company had been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection. This submission supports a potential multi-year, multi-million dollar contract to develop SuVax™ and MarVax™ vaccine candidates for use in the event of a Sudan ebolavirus or Marburg marburgvirus outbreak.
Merck announced today that the European Commission (EC) had approved an expanded indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age. VAXNEUVANCE is also indicated in Europe for adults.
In a revelation that may help the Republic of Uganda resolve the ongoing Sudan Ebolavirus (SUDV) outbreak, John Cohen with Science.org reported yesterday that the pharmaceutical firm Merck & Co., Inc. acknowledged that it has up to 100,000 doses of an experimental vaccine in its freezers in Pennsylvania.